Journal
BONE MARROW TRANSPLANTATION
Volume 45, Issue 6, Pages 1000-1007Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/bmt.2009.289
Keywords
cord blood; ex vivo expansion; inhibitory 'accessory' cells; mononuclear cells
Categories
Funding
- NCI [R01 CA061508-16]
- NATIONAL CANCER INSTITUTE [R01CA061508] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Cord blood (CB) is used increasingly in transplant patients lacking sibling or unrelated donors. A major hurdle in the use of CB is its low cell dose, which is largely responsible for an elevated risk of graft failure and a significantly delayed neutrophil and platelet engraftment. As a positive correlation has been shown between the total nucleated cell (TNC) and CD34(+) cell dose transplanted and time to neutrophil and platelet engraftment, strategies to increase these measures are under development. One strategy includes the ex vivo expansion of CB mononuclear cells (MNC) with MSC in a cytokine cocktail. We show that this strategy can be further improved if CD3(+) and/or CD14(+) cells are first depleted from the CB MNC before ex vivo expansion. Ready translation of this depletion strategy to improve ex vivo CB expansion in the clinic is feasible as clinical-grade devices and reagents are available. Ultimately, the aim of improving TNC and CD34(+) transplant doses is to further improve the rate of neutrophil and platelet engraftment in CB recipients. Bone Marrow Transplantation (2010) 45, 1000-1007; doi:10.1038/bmt.2009.289; published online 19 October 2009
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available